Aricept shows initial resilience to generic onslaught in Japan
This article was originally published in Scrip
If initial trends are anything to go by, Eisai does not have too much to fear from the advent of generic competition in Japan to its top product, the Alzheimer's disease therapy Aricept (donepezil).
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.